Open Access
29- https://doi.org/10.1053/j.gastro.2005.10.021
A Functional Role of Flip in Conferring Resistance of Crohn’s Disease Lamina Propria Lymphocytes to FAS-Mediated Apoptosis
Translate Article 
Take Notes There is evidence that, in Crohn's disease (CD), lamina propria T lymphocytes (LPLs) are resistant to FAS-mediated apoptosis and that this defect contributes to the mucosal T-cell accumulation. In this study we examined the functional role of Flip, a Flice inhibitor protein, in the resistance of CD LPL to FAS-mediated apoptosis. Biopsy specimens and LPLs were taken from CD and ulcerative colitis (UC) patients and normal controls and analyzed for Flip by Western blotting. We also examined whether inhibition of Flip by antisense oligonucleotide restored the susceptibility of CD LPLs to FAS-induced apoptosis. LPL apoptosis was assessed by flow cytometry. After FAS stimulation, the rate of apoptosis of CD3+ LPLs was higher in normal controls and patients with UC than in patients with CD. Enhanced expression of both long and short Flip isoforms was seen in biopsy specimens and purified CD3+ and CD45RO+ LPLs of CD patients in comparison with UC patients and normal controls. No increase in Flip was documented in untreated celiac disease mucosa, thus suggesting the possibility that induction of Flip in the gut does not simply rely on the ongoing inflammation. Finally, we showed that inhibition of Flip by antisense oligonucleotide reverted the resistance of CD LPLs to FAS-induced apoptosis. Data suggest a role for Flip in the resistance of CD LPLs to FAS-mediated apoptosis.
- Research Article
- 298
- 10.1053/j.gastro.2004.12.042
- Mar 1, 2005
- Gastroenterology
Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn’s disease
- Research Article
- 427
- 10.1053/j.gastro.2011.01.054
- Apr 28, 2011
- Gastroenterology
The Commensal Microbiota and Enteropathogens in the Pathogenesis of Inflammatory Bowel Diseases
- Front Matter
- 5
- 10.1053/j.gastro.2008.04.013
- May 16, 2008
- Gastroenterology
Neither Hide Nor Hair: The Difficulty of Identifying Useful Disease Biomarkers
- Research Article
- 14
- 10.1053/j.gastro.2022.06.026
- Jun 13, 2022
- Gastroenterology
Anti–Integrin αvβ6 Antibody as a Diagnostic Marker for Pediatric Patients With Ulcerative Colitis
- Research Article
- 38
- 10.2353/ajpath.2008.080222
- Aug 1, 2008
- The American Journal of Pathology
Substance P-Mediated Expression of the Pro-Angiogenic Factor CCN1 Modulates the Course of Colitis
- Research Article
- 133
- 10.1074/jbc.m413776200
- May 1, 2005
- Journal of Biological Chemistry
Nucleotide oligomerization domain 2 (NOD2) functions as a mammalian cytosolic pathogen recognition molecule, and variants have been associated with risk for Crohn disease. We recently demonstrated that NOD2 functions as an anti-bacterial factor limiting survival of intracellular invasive bacteria. To gain further insight into the mechanism of NOD2 activation and signal transduction, we performed yeast two-hybrid screening. We demonstrate that GRIM-19, a protein with homology to the NADPH dehydrogenase complex, interacts with endogenous NOD2 in HT29 cells. GRIM-19 is required for NF-kappaB activation following NOD2-mediated recognition of bacterial muramyl dipeptide. GRIM-19 also controls pathogen invasion of intestinal epithelial cells. GRIM-19 expression is decreased in inflamed mucosa of patients with inflammatory bowel diseases. GRIM-19 may be a key component in NOD2-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes.
- Front Matter
- 1
- 10.1016/j.cgh.2012.01.011
- Jan 28, 2012
- Clinical Gastroenterology and Hepatology
Predicting Outcomes After Restorative Proctocolectomy for Ulcerative Colitis
- Supplementary Content
- 102
- 10.1016/j.jcmgh.2014.11.006
- Dec 12, 2014
- Cellular and Molecular Gastroenterology and Hepatology
Mechanisms of Immune Signaling in Colitis-Associated Cancer
- Research Article
- 6
- 10.1053/j.gastro.2012.03.012
- Mar 23, 2012
- Gastroenterology
Variants in Autophagy Genes Affect Susceptibility to Both Crohn's Disease and Helicobacter pylori Infection
- Research Article
- 202
- 10.1016/j.cgh.2012.06.032
- Jul 16, 2012
- Clinical Gastroenterology and Hepatology
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
- Research Article
- 25
- 10.2353/ajpath.2006.060186
- Dec 1, 2006
- The American Journal of Pathology
Signal Transducer and Activator of Transcription 5b Promotes Mucosal Tolerance in Pediatric Crohn's Disease and Murine Colitis
- Front Matter
- 5
- 10.1053/j.gastro.2013.09.033
- Sep 21, 2013
- Gastroenterology
Does Consuming the Recommend Daily Level of Fiber Prevent Crohn's Disease?
- Front Matter
- 3
- 10.1053/j.gastro.2012.09.019
- Sep 20, 2012
- Gastroenterology
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas
- Research Article
- 41
- 10.1038/sj.jidsymp.5650029
- May 1, 2007
- Journal of Investigative Dermatology Symposium Proceedings
Modulation of the immune response with tumor necrosis factor (TNF) blockers is not a new treatment strategy for many inflammatory disorders; however, relatively little is known about their specific mechanism of action. Understanding the mode of action, pharmacology, and pharmacokinetics of the monoclonal TNF antibodies, infliximab and adalimumab, and the soluble TNF receptor, etanercept, may therefore enable us to account for their differing clinical profiles. The aim of this supplement is to explore the roles and mechanisms of TNF and TNF blockade using in vitro pharmacological and in vivo animal modeling experiments, and in vivo studies of the effects of etanercept on the inflammatory cascade in patients with psoriasis.
- Front Matter
- 25
- 10.1053/j.gastro.2003.12.020
- Feb 1, 2004
- Gastroenterology
Antibody responses in Crohn’s disease
- Ask R Discovery
- Chat PDF
